UPDATE — Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET NEW YORK, NY,…
News
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business
— Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12…
Treosulfan Pivotal Study Results Published
Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall…
Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
WARREN, N.J., June 06, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Amarin Appoints Tom Reilly as New Chief Financial Officer
— Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin —…
Xalud Therapeutics CEO to Participate in Two Gene Therapy Focused Panels at BIO International Convention 2022
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Xalud Therapeutics, a clinical-stage biotechnology company developing…
AltruBio to Present at the 2022 BIO International Convention
Judy Chou, Ph.D. President and CEO SAN FRANCISCO, June 06, 2022 (GLOBE NEWSWIRE) — AltruBio…
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022
REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR), a…
Madrigal Pharmaceuticals Supports International NASH Day on June 9
Company expands its partnerships with leading patient advocacy groups to improve NASH education and patient…
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and…
IO Biotech to Participate in the 2022 BIO International Convention
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as…
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB),…
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures…
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with…
Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy
– Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase…
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive…
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Trial will be the first clinical study of Allocetra™ in patients with cancer, following encouraging…
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
— Presentation at ASCO features updated results from Phase 2 ACCURACY study — — AL101…
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC),…